Waverley Pharma Inc. (TSX-V:WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly-owned  Barbados subsidiary, Waverley Pharma International Inc., has submitted abbreviated new drug applications with the United States Food and Drug Administration  for two high value anti-cancer generic drugs. The products were in-licensed and developed under a collaboration between Waverley Pharma International Inc. and Reliance Life Sciences Private Limited. The ANDA filings are the result of an exclusive product supply and development agreement executed on August 30, 2017, under which Waverley Pharma holds all commercial rights to the products in the United States, Canada and the European Union (excluding the United Kingdom, where Waverley Pharma has non-exclusive rights).

About Reliance Life Sciences

Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics. The Reliance Group is India’s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group’s flagship company, Reliance Industries Limited is India’s largest private sector company and a Fortune Global 500 company. RLS is a fully-integrated life sciences industry player with in-house capabilities in research, pre-clinical and clinical development, process development, commercial-scale manufacturing and marketing.

About Waverley Pharma

Waverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of effective and affordable cancer therapeutics in the EU and North American markets. The Company has recently acquired two generic drugs marketed in the United Kingdom, Capecitabine and Temozolomide.   Furthermore, Waverley Pharma has filed for marketing approval in selected countries of the EU and with the United States FDA for two additional high value generic oncology drugs and is currently evaluating other products, in different stages of development. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.